Explore

Trendline Trendline
Precision BioSciences to Present New Data on PBGENE-HBV at EASL Congress 2026

Precision BioSciences to Present New Data on PBGENE-HBV at EASL Congress 2026

Precision BioSciences to Present New Data on PBGENE-HBV at EASL Congress 2026
Trendline Trendline
Rosen Law Firm Urges Atara Biotherapeutics Investors to Act Before Class Action Deadline

Rosen Law Firm Urges Atara Biotherapeutics Investors to Act Before Class Action Deadline

Rosen Law Firm Urges Atara Biotherapeutics Investors to Act Before Class Action Deadline
Trendline Trendline
4Moving Biotech's 4P004 Receives FDA Fast Track Designation for Knee Osteoarthritis Treatment

4Moving Biotech's 4P004 Receives FDA Fast Track Designation for Knee Osteoarthritis Treatment

4Moving Biotech's 4P004 Receives FDA Fast Track Designation for Knee Osteoarthritis Treatment
Trendline Trendline
Vir Biotechnology Announces Upcoming Conference Call to Discuss Q1 2026 Financial Results

Vir Biotechnology Announces Upcoming Conference Call to Discuss Q1 2026 Financial Results

Vir Biotechnology Announces Upcoming Conference Call to Discuss Q1 2026 Financial Results
Trendline Trendline
Plus Therapeutics Initiates Manufacturing Activities for CNS Cancer Drug REYOBIQ

Plus Therapeutics Initiates Manufacturing Activities for CNS Cancer Drug REYOBIQ

Plus Therapeutics Initiates Manufacturing Activities for CNS Cancer Drug REYOBIQ
Trendline Trendline
Spruce Biosciences Prices Public Offering to Raise $60 Million

Spruce Biosciences Prices Public Offering to Raise $60 Million

Spruce Biosciences Prices Public Offering to Raise $60 Million
Trendline Trendline
Spruce Biosciences Initiates Public Offering of Common Stock and Pre-Funded Warrants

Spruce Biosciences Initiates Public Offering of Common Stock and Pre-Funded Warrants

Spruce Biosciences Initiates Public Offering of Common Stock and Pre-Funded Warrants
Trendline Trendline
Spruce Biosciences Launches Public Offering to Fund Neurological Therapies

Spruce Biosciences Launches Public Offering to Fund Neurological Therapies

Spruce Biosciences Launches Public Offering to Fund Neurological Therapies
Trendline Trendline
Spruce Biosciences Sets Pricing for Public Offering of Common Stock and Pre-Funded Warrants

Spruce Biosciences Sets Pricing for Public Offering of Common Stock and Pre-Funded Warrants

Spruce Biosciences Sets Pricing for Public Offering of Common Stock and Pre-Funded Warrants
Trendline Trendline
Alpha Cognition Appoints Bethany Sensenig to Board, Enhancing Strategic Leadership

Alpha Cognition Appoints Bethany Sensenig to Board, Enhancing Strategic Leadership

Alpha Cognition Appoints Bethany Sensenig to Board, Enhancing Strategic Leadership
Trendline Trendline
Rosen Law Firm Urges Nektar Therapeutics Investors to Act Before Class Action Deadline

Rosen Law Firm Urges Nektar Therapeutics Investors to Act Before Class Action Deadline

Rosen Law Firm Urges Nektar Therapeutics Investors to Act Before Class Action Deadline
Trendline Trendline
Eluciderm, Inc. Awarded for Innovative Wound Healing Research with ELU42

Eluciderm, Inc. Awarded for Innovative Wound Healing Research with ELU42

Eluciderm, Inc. Awarded for Innovative Wound Healing Research with ELU42